With all due respect, there is no point in doing comparisons...

With all due respect, there is no point in doing comparisons between two different studies which in all likelihood have different parameters. You could well be comparing apples with oranges.

Phase 1 trials are typically small. And, if the trial you are referring to is this one: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9826661/ ... then you are comparing apples with oranges.

Its a Ph 2 trial and the results pertain to a combination therapy! Twice the chance of the data being better than CHM-101.

Essentially, 101 is being trialed as a monotherapy... big difference, And, the recruitment target is for 42 patients.

This is a phase 1b study to evaluate the safety of chimeric antigen receptor (CAR) T cells with a chlorotoxin tumor-targeting domain (ie, CHM-1101, the study treatment) to determine the best dose of CHM-1101, and to assess the effectiveness of CHM-1101 in treating MMP2+ glioblastoma that has come back (recurrent) or that is growing, spreading, or getting worse (progressive).